Abstracts Archive - Page 200 of 1683 - ATC Abstracts

2021 American Transplant Congress
Accounting for Survivor Bias in Transplant Benefit Models
E. M. Schnellinger¹, E. Cantu², M. O. Harhay¹, D. E. Schaubel¹, S. E. Kimmel¹, A. J. Stephens-Shields¹
¹Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Department of Surgery, Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: The lung allocation system in the U.S. prioritizes lung transplant candidates based on estimated pre- and post-transplant survival. However, these models do not account…
2021 American Transplant Congress
Quantification of Multiple Isotypes of Anti-SARS-CoV-2 Antibodies in Kidney Transplant Recipients
J. S. Maltzman¹, L. Wang¹, P. Ahearn¹, T. Yalamarti¹, M. Menon², Y. Azzi³, M. Melcher¹, M. Fernandez-Vina¹, R. Bray⁴, H. Gebel⁴, E. Woodle⁵, E. Akalin³, A. Girnita¹, P. Cravedi²
¹Stanford University, Palo Alto, CA, ²Icahn School of Medicine, NYC, NY, ³Einstein School of Medicine, NYC, NY, ⁴Emory University, Atlanta, GA, ⁵University of Cincinnati, Cincinnati, OH
*Purpose: Solid organ transplant recipients are at increased risk of severe outcomes with infection by SARS-CoV-2, the etiologic agent of COVID-19. Antibodies directed against the…
2021 American Transplant Congress
Early Review of Liver Acuity Circles Allocation
S. Noreen¹, J. Heimbach², J. Pomposelli³, M. Cafarella¹, J. Trotter⁴
¹UNOS, Richmond, VA, ²Mayo Clinic, Rochester, MN, ³UCHealth, Aurora, CO, ⁴BSWHealth, Dallas, TX
*Purpose: Acuity circles (AC) allocation was implemented on February 4, 2020, followed shortly by the declaration of national emergency for COVID-19. The goal of this…
2021 American Transplant Congress
Nurse and Nurse Practitioner-lead Monoclonal Antibody Initiative for Solid Organ Transplant (sot) Recipients with Covid-19
W. Cochran¹, R. Avery², D. Brennan², N. Lawrence², A. Brown², S. Sullivan², B. Adams², M. McCarthy², S. Ellis², F. Naqvi², E. Kraus², N. Alachkar², S. Alasfar², F. Al Ammary², J. Horn², L. Hartman², L. Fessler², S. Purekal², Z. Siddiqui², D. Carter², J. Ficke², M. Kantsiper², L. Boyer², I. Gupta², A. Gurakar², D. Ostrander², J. Langlee², S. Shoham², K. Marr², P. Shah²
¹Johns Hopkins Comprehensive Transplant Center, Baltimore, MD, ²Johns Hopkins, Baltimore, MD
*Purpose: Monoclonal antibody (mAB) infusion (bamlanivimab or casirivimab/imdevimab) for symptomatic, non-hypoxemic, high-risk outpatients with COVID-19 infection, is an available early intervention for COVID-19+ SOT recipients.…
2021 American Transplant Congress
The Impact of Thromboelastography on Decreasing Blood Product Usage in Liver Transplantation
A. Mohamed¹, T. Kitajima¹, S. Angappan², K. Delvecchio¹, A. M. Elsabbagh¹, S. Yeddula¹, M. Shamaa¹, K. Collins¹, M. Rizzari¹, A. Yoshida¹, M. Abouljoud¹, J. El-Bashir², S. Nagai¹
¹Department of Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, ²Department of Anesthesiology, Henry Ford Hospital, Detroit, MI
*Purpose: Liver dysfunction results in derangement of hemostasis and thrombosis. Thromboelastography (TEG) has emerged as a tool to guide resuscitative efforts. However, its utilization and…
2021 American Transplant Congress
High Levels of Sars-cov-2 Detected in Immunosuppressed Covid-19 Patient Environments Weeks Following Initial Positive Test
C. E. Kuschner¹, Z. Brune², L. B. Becker¹, L. Teperman¹
¹North Shore University Hospital, Manhasset, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY
*Purpose: COVID-19 is a novel viral illness associated with significantly worse mortality, prolonged disease course, and extended periods of viral shedding in transplant patients on…
2021 American Transplant Congress
Donor Derived Cell-Free DNA (dd-cfDNA) in Pancreas Transplant Recipients
S. Riad¹, H. Sarumi², R. Kandaswamy³
¹Medicine, University of Minnesota, Minneapolis, MN, ²Surgery, University of Minnesota Physicians, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Data on the role of DD-cfDNA after pancreas transplantation is lacking. Herein we report on our center experience with DD-cfDNA in 10 unique SPK…
2021 American Transplant Congress
One-Year Monitoring of Changes to Kidney-Pancreas Waiting Time Criteria: An OPTN Analysis
R. C. Forbes¹, B. Plucinski², J. White², N. T. Kyaw², R. Kandaswamy³, S. V. Niederhaus⁴
¹Surgery, Vanderbilt University, Nashville, TN, ²UNOS, Richmond, VA, ³Surgery, University of Minnesota, Minneapolis, MN, ⁴Surgery, University of Maryland, Baltimore, MD
*Purpose: In 2018, the OPTN board approved changes to kidney-pancreas (KP) waiting time criteria. KP candidates accrued waiting time if they were (1) on insulin…
2021 American Transplant Congress
Body Mass Index >35 Does Not Impact Kidney Transplant Outcomes or Health Related Quality of Life Despite BMI Class or Recipient Race
D. A. Walczak¹, E. Collins², E. Benedetti¹
¹Organ Transplant, University of Il Hospital and Health Sciences System, Chicago, IL, ²College of Nursing, Dept of Bio-behavioral Health Science, University of Illinois at Chicago, Chicago, IL
*Purpose: Kidney transplant [KTx] in recipients with BMI > 35 remains controversial and has not often been studied in recipients with BMI >40. There is…
2021 American Transplant Congress
Genetic versus Self-reported African Ancestry and Kidney Allograft Outcome: Analysis of Two Large Multiethnic Urban Transplant Cohorts
F. Zanoni¹, D. Neugut¹, S. Mohan¹, A. Gharavi¹, B. Keating², K. Kiryluk¹
¹Department of Medicine, Division of Nephrology, Columbia University, New York, NY, ²Department of Surgery, Division of Transplantation, University of Pennsylvania, Philadelphia, PA
*Purpose: African-American (AA) kidney transplant recipients (KTx) have higher risk of rejection and failure. However, it is unknown to what extent the inferior outcomes in…